Literature DB >> 36178508

Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.

Kinga Kamińska1, Tomasz Lenda1, Jolanta Konieczny1, Elżbieta Lorenc-Koci2.   

Abstract

RATIONALE: The pharmacological effects of antidepressants in modulating noradrenergic transmission as compared to serotonergic transmission in a rat model of Parkinson's disease under chronic L-DOPA therapy are insufficiently explored.
OBJECTIVES: The aim of the present study was to investigate the effect of the tricyclic antidepressant desipramine administered chronically alone or jointly with L-DOPA, on motor behavior and monoamine metabolism in selected brain structures of rats with the unilateral 6-OHDA lesion.
METHODS: The antiparkinsonian activities of L-DOPA and desipramine were assessed behaviorally using a rotation test and biochemically based on changes in the tissue concentrations of noradrenaline, dopamine and serotonin and their metabolites, evaluated separately for the ipsi- and contralateral motor (striatum, substantia nigra) and limbic (prefrontal cortex, hippocampus) structures of rat brain by HPLC method.
RESULTS: Desipramine administered alone did not induce rotational behavior, but in combination with L-DOPA, it increased the number of contralateral rotations more strongly than L-DOPA alone. Both L-DOPA and desipramine + L-DOPA significantly increased DA levels in the ipsilateral striatum, substantia nigra, prefrontal cortex and the ipsi- and contralateral hippocampus. The combined treatment also significantly increased noradrenaline content in the ipsi- and contralateral striatum, while L-DOPA alone decreased serotonin level on both sides of the hippocampus.
CONCLUSIONS: The performed analysis of the level of monoamines and their metabolites in the selected brain structures suggests that co-modulation of noradrenergic and dopaminergic transmission in Parkinson's disease by the combined therapy with desipramine + L-DOPA may have some positive implications for motor and psychiatric functions but further research is needed to exclude potential negative effects.
© 2022. The Author(s).

Entities:  

Keywords:  Contralateral rotations; Depressive-like behavior; Desipramine; L-DOPA; Monoamine levels; Unilateral 6-OHDA lesion

Mesh:

Substances:

Year:  2022        PMID: 36178508      PMCID: PMC9584871          DOI: 10.1007/s00213-022-06238-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  152 in total

1.  Distribution of dopamine beta-hydroxylase-like immunoreactive fibers within the shell subregion of the nucleus accumbens.

Authors:  C W Berridge; T L Stratford; S L Foote; A E Kelley
Journal:  Synapse       Date:  1997-11       Impact factor: 2.562

2.  Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals.

Authors:  E Carboni; G L Tanda; R Frau; G Di Chiara
Journal:  J Neurochem       Date:  1990-09       Impact factor: 5.372

3.  Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.

Authors:  Stefania Fasano; Erwan Bezard; Angela D'Antoni; Veronica Francardo; Marzia Indrigo; Li Qin; Sandra Doveró; Milica Cerovic; M Angela Cenci; Riccardo Brambilla
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-29       Impact factor: 11.205

4.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

Authors:  G M Halliday; P C Blumbergs; R G Cotton; W W Blessing; L B Geffen
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

5.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

Authors:  Manolo Carta; Thomas Carlsson; Deniz Kirik; Anders Björklund
Journal:  Brain       Date:  2007-04-23       Impact factor: 13.501

Review 6.  Differential cognitive actions of norepinephrine a2 and a1 receptor signaling in the prefrontal cortex.

Authors:  Craig W Berridge; Robert C Spencer
Journal:  Brain Res       Date:  2015-11-22       Impact factor: 3.252

Review 7.  Noradrenaline in Parkinson's disease: from disease progression to current therapeutics.

Authors:  Francesco Fornai; Adolfo Bandettini di Poggio; Antonio Pellegrini; Stefano Ruggieri; Antonio Paparelli
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 8.  Norepinephrine: The redheaded stepchild of Parkinson's disease.

Authors:  K S Rommelfanger; D Weinshenker
Journal:  Biochem Pharmacol       Date:  2007-02-03       Impact factor: 5.858

9.  The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.

Authors:  John Liggins; Robert O Pihl; Chawki Benkelfat; Marco Leyton
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

10.  Norepinephrine: the next therapeutics frontier for Parkinson's disease.

Authors:  Peter A Lewitt
Journal:  Transl Neurodegener       Date:  2012-01-13       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.